GlassScriptPhysician profile
Karla D Mccann
NPI 1730162538
$1,999.33
in general payments reported to CMS, 2019-2025
30 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2023: $220 · 2024: $411 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $459.69 | 2019-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $345.06 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $142.97 | 2019-2025 | |
| Lilly USA, LLC | $132.48 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $107.50 | 2019-2024 | Repatha, Otezla |
| Tactile Systems Technology INC | $73.86 | 2019 | |
| Phathom Pharmaceuticals, INC. | $59.54 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $58.38 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.89 | 2023-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $48.21 | 2019 | |
| Abbvie INC. | $48.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $43.64 | 2019 | |
| Amarin Pharma, INC. | $43.36 | 2019 | |
| Currax Pharmaceuticals LLC | $43.02 | 2023-2025 | Contrave, Onzetra Xsail |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $35.80 | 2024-2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $31.62 | 2019 | |
| Edwards Lifesciences Corporation | $24.90 | 2023 | |
| Novartis Pharmaceuticals Corporation | $21.60 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.23 | 2023 | Horizant |
| Exact Sciences Corporation | $19.07 | 2025 | Cologuard Collection Kit |
| Mirum Pharmaceuticals, INC. | $17.31 | 2023 | |
| Astellas Pharma US INC | $16.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.49 | 2024 | Eliquis |
| Daiichi Sankyo INC. | $14.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.94 | 2025 | Zoryve |
| Axsome Therapeutics, INC. | $14.88 | 2025 | Auvelity |
| Allergan, INC. | $13.71 | 2019 | |
| Merck Sharp & Dohme LLC | $11.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Mccann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.